Monopar Therapeutics (MNPR) Net Income Growth (3y) (2020 - 2025)
Monopar Therapeutics (MNPR) Net Income Growth (3y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 47.10% |
| 10 | Monopar Therapeutics | 809.66 Mn | 747.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -20.99% |
| Jun 30, 2025 | 3.27% |
| Mar 31, 2025 | -9.38% |
| Sep 30, 2024 | 15.65% |
| Jun 30, 2024 | 5.13% |
| Mar 31, 2024 | 3.47% |
| Sep 30, 2023 | -5.84% |
| Jun 30, 2023 | -17.06% |
| Mar 31, 2023 | -29.92% |
| Dec 31, 2022 | -52.38% |
| Sep 30, 2022 | -46.48% |
| Jun 30, 2022 | -44.33% |
| Mar 31, 2022 | -19.85% |
| Dec 31, 2021 | -58.40% |
| Sep 30, 2021 | -53.86% |
| Jun 30, 2021 | -45.26% |
| Mar 31, 2021 | -27.23% |
| Dec 31, 2020 | -62.67% |
| Sep 30, 2020 | 52.00% |
| Jun 30, 2020 | -35.01% |